|
|
News Breaks | | | | December 27, 2012 | | 16:21 EDT |  | AMGN, ABC | Amgen gets court approval in previously announced $762M settlement with FDA
U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by Amgen (AMGN) for illegally introducing a misbranded drug into interstate commerce, and approved Amgen’s global settlement with the United States in which Amgen agreed to pay $762M to resolve criminal and civil liability arising from its sale and promotion of certain drugs. Under the terms of the criminal plea agreement, Amgen will pay a criminal fine of $136M and criminal forfeiture in the amount of $14M. As part of the civil settlement, Amgen has agreed to pay $612M, of which $587.2M is to the United States and $24.8M to the states, to resolve claims that it caused false claims to be submitted to Medicare, Medicaid and other government insurance programs. In a separate civil settlement, International Nephrology Network, renamed Integrated Nephrology Network, a subsidiary of AmerisourceBergen Corporation (ABC), has also agreed to pay $15M to resolve civil liability arising from its role in the marketing of Aranesp. Reference Link | |
|
News For AMGN;ABC From The Last 14 Days Check below for free stories on AMGN;ABC the last two weeks. |
|
|
| May 17, 2013 | | 12:33 EDT | | ABC | AmerisourceBergen receives approval of Walgreens, Alliance Boots investment
AmerisourceBergen (ABC) announced that the parties have received regulatory approval of the previously disclosed agreement for Walgreen (WAG) and Alliance Boots GmbH to purchase an equity stake in the company. AmerisourceBergen continues to expect the new agreements to contribute an incremental $25B in revenues and approximately 20c in earnings per share in FY14, excluding the amortization of certain expenses related to the transaction and the warrants issued, certain non-recurring costs and a potential LIFO charge, and net of certain start up expenses. In addition, the company reiterated its expectations for financial performance for fiscal year 2013, which includes expected revenue growth in the 11%-13% range, and diluted earnings per share from continuing operations in the lower half of the range of $3.04 to $3.14, excluding certain expenses related to the relationship with Walgreens and Alliance Boots and the warrants issued, and the expected LIFO charge from onboarding of additional branded inventory. | | | May 14, 2013 | | 07:18 EDT |  | ABC | BofA/Merrill to host a conference
2013 Health Care Conference is being held in Las Vegas on May 14-16. | | | May 13, 2013 | | 08:55 EDT |  | AMGN | Biosimiliar drug bill to be taken up in Senate, LA Times reports
 Subscribe for More Information | | | 08:05 EDT | | ABC | Frazier Healthcare acquires AnderesonBrecon from AmerisourceBergen
Subscribe for More Information | | | 07:32 EDT | | ABC | AmerisourceBergen says divestiture of AndersonBrecon has no impact on guidance
Subscribe for More Information | | | May 9, 2013 | | 16:48 EDT | | AMGN | Amgen, Zhejiang Beta Pharma announce joint venture in China
Subscribe for More Information | |
|
|
|
|
|
|
